The HNSCC TME is both a central barrier and an attractive therapeutic target. Embedding high-resolution TME profiling into clinical trials will be crucial to select TME-matched combinations and identify patient subsets most likely to derive durable benefit from immunotherapy.
Tinhofer et al. (2026) studied this question.